Biosimilars lining up to compete with Herceptin-opportunity knocks

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 11, 2014, Pages 1149-1153

  Nelson, Kevin M ^a   Gallagher, Patrick C ^a  

^a Duane Morris LLP   (United States)

Author keywords

Biologics (biological drug products); Biosimilars; FDA; Herceptin ; Monoclonal antibodies; Patents; Trastuzumab

Indexed keywords

BIOSIMILAR AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; GENE OVEREXPRESSION; HEALTH CARE COST; HUMAN; PATENT; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STOMACH CANCER; UNITED STATES; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; ECONOMICS; FEMALE; GENETICS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; BREAST NEOPLASMS; FEMALE; HUMANS; PATENTS AS TOPIC; RECEPTOR, ERBB-2;

EID: 84911471334     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.964683     Document Type: Review

References (34)

1. Herceptin Full Prescribing Information. 2014.Available from: http://www.gene.com/download/pdf/herceptin-prescribing. pdf [Last accessed 22 September 2014]
2. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80
3. Herceptin (Trastuzumab) Proposed Mechanism of Action. Genentech, 2014.Available from: http://www.gene.com/media/product-information/herceptin-moa [Last accessed 14 July 2014]
4. Goldenberg MM. Pharmaceutical approval update. P T 2012;37:499-502
5. Herceptin-Historical sales 1998-2008. Available from: www.gene.com/about-us/investors/historical-products-sales/herceptin [Last accessed 15 July 2014]
6. Roche Financial Reports from 1999-2013. Available from: www.roche.com/investos/annual-reports-archive.htm [Last accessed 15 July 2014]
7. Hirschler B. Hospira wins UK case to overturn patents on Roche drug Herceptin. Reuters, 2014.Available from: http://www.reuters.com/article/2014/04/10/us-roche-hldghospira-idUSBREA3916H20140410 [Last accessed 21 May 2014]
8. - 42 U.S.C. 262(k
9. Bagcchi S. Two companies blocked from comparing their generic products to Herceptin in India. BMJ 2014;348:g1632
10. Celltrion's Herzuma (trastuzumab) now approved in S. Korea. Biosimilar News, 2014.Available from: http://www.biosimilarnews.com/celltrions-herzumatrastuzumab-now-approved-in-s-korea [Last accessed 14 July 2014]
11. Hospira UK Limited v. Genentech Inc., (2014) EWHC 1094 (Pat
12. Hospira Biosimilars Policy. Hospira's Commitment to Adoption of Biosimilars in the United States. Available from: http://www.hospira.com/about-hospira/government-affairs/biosimilars-policy/index [Last accessed 3 June 2014]
13. PlantForm Products page. Available from: www.plantformcorp.com/products/aspx [Last accessed 15 July 2015]
14. ViewPoints: amgen looks to leapfrog rivals in Herceptin biosimilar race with Phase III trial in early stage breast cancer patients. FirstWord Pharma. Available from: http://www.firstwordpharma.com/print/1077937?tsid=17 [Last accessed 22 August 2014]
15. Available from: http://clinicaltrials.gov/show/NCT01901146 [Last accessed 22 August 2014]
16. Available from: http://clinicaltrials.gov/show/NCT01901146 [Last accessed 22 August 2014]
17. Pfizer to start phase III biosimilar trastuzumab trial. GaBi Online, posted 6 Feb 2014.Available from: http://www.gabionline.net/Biosimilar/News/Pfizer-tostart-phase-III-biosimilar-trastuzumabtrial [Last accessed 22 August 2014]
18. Available from: http://clinicaltrials.gov/show/NCT01989676 [Last accessed 22 Augest 2014]
19. Available from: http://clinicaltrials.gov/show/NCT01989676 [Last accessed 22 Augest 2014]
20. U.S. Patent No. 5,677,171
21. U.S. Patent No. 6,339,142
22. U.S. Patent No. 6,627,196
23. U.S. Patent No. 7,074,404
24. U.S. Patent No. 7,371,379
25. U.S. Patent Application Publication No US 2014-0079692-A1
26. Harbeck N, Beckmann MW, Rody A, et al. HER2 dimerization inhibitor pertuzumab-Mode of action and clinical data in breast cancer. Breast Care (Basel) 2013;8:49-55
27. Pertuzumab Full Prescribing Information. 2013.Available from: http://www.gene.com/download/pdf/perjeta-prescribing. pdf [Last accessed 22 September 2014]
28. Stanton T. Roche's Perjeta proves a fast fave with cancer docs, but Kadcyla's a speed racer. Fierce PharmaMarketing (March 19, 2014 Available from: http://www.fiercepharmamarketing.com/story/roches-perjeta-proves-fast-fave-cancerdocs-kadcylas-speed-racer/2014-03-19 [Last accessed 15 July 2014]
29. Poon KA, Flagella K, Beyer J, et al. Preclinical safety profile of trastuzumab emtasnsine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol 2013;273:298-313
30. Kadcyla Full Prescribing Information. 2013.Available from: http://www.gene.com/download/pdf/kadcyla-prescribing. pdf [Last accessed 22 September 2014]
31. Zolot RS, Basu S, Million RP. Antibodydrug conjugates. Nat Rev Drug Discov 2013;21:259-60
32. A Study of Trastuzumab Emtansine (TDM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). Clinical Trial Protocol Registry, Roche Trials Database. Available from: http://www.roche-trials.com/trialDetailsGet. action?studyNumber=BO22589 [Last accessed 14 July 2014]
33. Congressional Budget Office Cost Estimate, S.1695 Biologics Price Competition and Innovation Act of 2007, Congressional Budget Office, 2008
34. Grabowski H, Long G, Mortimer R. Implementation of the biosimilar pathway: economic and policy issues. Seton Hall Law Rev 2011;41:511-57